Abstract
We compared adverse events among breast-feeding neonates born to Kenyan mothers receiving triple-antiretroviral therapy, including either nevirapine or nelfinavir. Nevirapine-exposed infants had an absolute increase in the risk of rash but no significant risk differences for hepatotoxicity or high-risk hyperbilirubinemia compared with nelfinavir-exposed infants. From an infant-safety perspective, nevirapine-based regimens given during pregnancy and breast-feeding are viable options where alternatives to breast milk are not safe, affordable or feasible.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aging, Premature
-
Anti-HIV Agents / adverse effects*
-
Anti-HIV Agents / therapeutic use*
-
Chemical and Drug Induced Liver Injury / blood*
-
Chemical and Drug Induced Liver Injury / pathology
-
Drug Eruptions / etiology
-
Drug Eruptions / pathology
-
Female
-
HIV Infections / drug therapy*
-
Humans
-
Hyperbilirubinemia / chemically induced*
-
Infant, Newborn
-
Infectious Disease Transmission, Vertical / prevention & control*
-
Kenya / epidemiology
-
Nelfinavir / adverse effects
-
Nelfinavir / therapeutic use
-
Nevirapine / adverse effects
-
Nevirapine / therapeutic use
-
Pregnancy
Substances
-
Anti-HIV Agents
-
Nevirapine
-
Nelfinavir